to house the first four soul programs. Once the fourth level is reached and then completed; it becomes the fifth soul program. Just as each soul level brings Consciousness into a higher level of reality; the obtainment of the fifth soul program results in an entrance to a new higher plane of reality. In religious circles, this higher plane is termed "heaven." The result is a new higher body form as well to complement the new plane.
"Enoch walked faithfully with God; then he was no more, because God took him away."
Let the reader understand, the taking away of Enoch is not an indication that Elohim: the gods "took him away" to another planet or something of that nature. No! The phrase, "was no more" in the above verse speaks volumes to the notion that Enoch was no longer living in this realm of reality.
The phrase, "was no more" is actually one word in the Hebrew Torah's Genesis account. The phrase is taken from the Hebrew word, "ayin," and is defined: "to be nothing or not exist; a non-entity" (Strong's H369). Enoch was no longer an entity of this plane, but had crossed over.
Of course it would be through eminent piety that the biblical character Enoch "walked with God;" setting the mindset of God always before himself. And reaching the fifth level of soul programing (becoming complete) during the duration of his life on earth; he was taken from this life.
Where the New Testament Bible's book of Hebrews state, "taken from this life," "taken him away" and "he was taken;" the Greek word used in all three phrases is "metatithemi." The literal English translation is Enoch "was taken up." The Greek word, "metatithemi" root meaning is "transfer, change sides." The Greek word literally means, "to go over to another party" (Strong's G3346).
Unlike Enoch who "did not experience death;" in the epics of the Christian Bible's Gospels; Jesus reached the climax of the fourth soul level, and thus, entered the fifth through his death (i.e. by ransoming his life on the behalf of his enemies,) no longer needing to be born into this world again. Through his selfless act he received his resurrected body and opened a door for those who would believe on his sacrifice and would emulate him with their own lives (i.e. becoming living sacrifices while living on earth) that they shall never have to be reincarnated into this reality again and would be able to move on to the next plane of life.
In the New Testament's book of Revelations, Jesus is recorded as saying, he possess the keys of death and Hades (Revelations 1: 18).
According to the Illumine, there is no true sense of death for the Conscious Observer: only different states of reality we will reside in. Nothing within this physical system we call our universe truly goes out of existence. This is what was meant when the serpent said to Eve in the Garden of Eden epic: "You shall not surely die" (cf. Genesis 3: 5).
All the ancient Mystery schools and great ancient cultures of old taught what all the major secret societies teach today, and that being: Consciousness (religious terminology: Spirit) is without end!
As for the avatar body that houses Consciousness, its physical composition is made of what we term, "matter" as is all of physical reality. And according to science, all the physicality's of reality are also without end!
In Albert Einstein's famous equation: E = MC2, mass (i.e. matter) and energy are regarded as interconvertible manifestations of the same phenomenon. His equation states: "energy" regularly changes into "matter" and vice versa. This is to say, in this universe there is a set amount of what we term as "energy matter" and the two, "energy" and "matter" is interchangeable. When equated together; the total amount of energy and matter in our universe always remains constant, but the ratio between energy and matter is continually changing. Thus, our entire physical universe is nothing more than energy existing in different forms (i.e. forms of radiation, light waves, matter and etc.) What we term "matter" continues this cycle of changing forms without end!
According to the Illumine, life for the Conscious Observer is also an ongoing cycle: but in the realm of reincarnations (i.e. being born over and over again in this state of physical reality) until completion (Godhead) is reached. When people "die" (in the sense of the avatar body failing); the Conscious Observer enters into what the Bible' New Testament calls. "Hadés" as the Conscious Observer await their reentry back into this reality through the birth canal.
Hadés is the vessel of death, a reality unseen by the naked eyes. The Greek term "Hadés" is literally defined this way, "the abode of departed spirits, the unseen world" (Strong's G86).
Obtaining completion, i.e. the fifth level of soul program, and what the Christian Bible terms, the "Godhead," comes by obtaining a mindset of complete selflessness. Yes, selflessness is the mountain of life one must climb in becoming complete.
The Illumine informs its initiates that there is a higher plane of reality then what we now exist in. But the next stage of higher life is totally hidden from the Conscious Observer that lives their life in the first three soul levels; and is partially revealed to the Conscious Observer that lives their life in the fourth soul level, which is a level considered by religious folk as one having a spiritual mind (being sincerely pious).
"…. what we will be has not yet been revealed. We know that when Christ appears, we will be like Him, for we will see Him as He is.
Above: a drawing of the human avatar standing on top of the masculine and feminine symbols of life, along with the final five emanations of the Tree of Life, exhibiting the energy fields produced from the avatar creation.
Note: no matter what kind of avatar body type we are addressing: a worm, a dog, or a human; the soul (mind) is the major component of the avatar body. But unlike, let's say, the worm, who can only fulfill the first level of soul programing, and, let's say, the dog, who can only fulfill the second level of soul programing; through the human avatar body; Consciousness is able to experience all four soul levels – plus, as the biblical story of Enoch goes with his ascension, and the biblical story of Jesus with his resurrected body; a fifth and final level of soul programing, which houses enormously high vibratory frequencies. Therefore, Consciousness through the soul program of the human avatar body can correspond with reality on much higher frequencies than that of the other avatar body types fashioned on earth, which possess restrictions, e.g. the worm, the dog and etc.
As mentioned earlier in this chapter, there is no true sense of death for the Conscious Observer; only states of reality. Life for the Conscious Observer is a cycle of reincarnations (i.e. being born over and over again on this plane, or rather, in this state or reality) until completion, i.e. Godhead is achieved.
Humanity was made higher than earth's animal kingdom by the giving of the "breath of life" (i.e. the Neshamah: third level of soul programing), but a little lower than Elohim: the gods of Genesis because; the gods operate out of Yechida: the Godhead. Therefore, humanity must obtain on their own the final two levels of soul programing (i.e. Chayah and Yechida). And as the Bible verse from above states: through humanity's ascension of the levels of soul programs; they will be "crowned…. with glory and honor" (i.e. crowned with Godhead) as Jesus was (cf. Colossians 2: 9).
The human avatar was made in the "image" and "likeness" of Elohim: the gods of Genesis. In the human avatar there would be no restriction on levels of soul in reaching Yechida (Godhead). Thus, the gods of Genesis gave humanity dominion over the fish of the sea, and over the fowl of the air, and over the cattle, and over all the earth, and over every creeping thing that creeps upon the earth.


CPWR provides practical information for workers, contractors, trainers, researchers, and others through all media. Publications-some in Spanish-include hazard alerts for workers, The Construction Chart Book and other research reports, and the CPWR UPDATE newsletter. In addition to producing videos and DVDs, CPWR organizes conferences for stakeholders, and provides web-based information, including this website and several other web resources.
User Tip: Click on the document title - listed above the image - to view the featured publication.
To view all material available in each category, select the link below the image in red.
Email CPWR-R2P@cpwr.com or Sharretta Benjamin at 301-495-8500.


Domingo Gonzalez, age 83, of Lorain, passed away Thursday, January 17, 2019 at his residence while under the care of Stein Hospice following a lengthy illness.
Born November 15, 1936 in Arecibo, Puerto Rico, he lived in Florida before coming to Lorain in the early 1980's.
He was a member of Iglesia de Dios Casa de Oracion, Lorain. Domingo enjoyed playing his guitar, gardening and he loved animals.
Surviving is his wife of 59 years, Rosa (nee Soto); a son, Jose of Lorain; daughters, Rosa Gonzalez of Cleveland and Iris Sanchez of Lorain; 8 grandchildren and 12 great grandchildren; brothers, Feliciano and Juan all of Puerto Rico; and a sister, Beatrice Gonzalez of New Jersey.
He was preceded in death by his parents, Justo and Regina (nee Centeno) Gonzalez; and a brother, Santos; sisters, Otilia Gonzalez, Maria Gonzalez and Fermina Gonzalez.
The family will receive friends on Sunday from 2:00 pm to 6:00 pm in the Dovin Funeral and Cremation Specialists, 2701 Elyria Avenue, Lorain. The family will also receive friends on Monday from 9:00 am until the time of funeral services at 10:00 am at Iglesia de Dios Casa de Oracion, 1600 E. 34th Street, Lorain. Burial will follow in Ridge Hill Memorial Park, Amherst Twp.


I've started working with clients and groups using sound (crystal bowls, voice, and instruments) and their responses have been nothing short of amazing.
Others say how deeply relaxed and refreshed they feel, the shifts they experience, insights, releases, visions, and connection with guides and spirits.
I've had many wonderful experiences with healing sounds.
Once, I had a sprained knee which ached quite abit. While leading a chant group, I experimented by resting my tanpura (an Indian drone instrument) against it. After the hour, my pain completely vanished! Since then, I use it on people's bodies while I'm sound healing.
I'm completely fascinated and passionate about the power and possibility sound healing has for humanity and our planet.
Heals (and speaks) to your body on cellular levels.
Stimulates and strengthens all your systems and organs — endocrine, circulation, digestion, heart, brain, immune, and hormonal.
Leads you into very deep states of relaxation to de-stress and get out of your non-stop mind.
Balances and connects your left and right brain hemispheres.
Cleanses your body and energy field of negative energy, toxins, andstuck emotions, and helps you release whatever you're ready to release.
Sings your body back to its original song and harmonics.
Connects you with your spirituality. You might even connect with your guides and beings of Light and Love.
Opens you to fresh, expanded perspectives and insights.
Activates your third eye (pituitary gland), pineal gland, and intuition.
Helps you feel refreshed, whole, restored.
Sound medicine is a healing modality that uses the law of vibration to heal your body, mind, heart, and soul.
Sound medicine is based on the principle that you are energy. Your bones, your muscles, your organs, your thoughts, and your feelings.
Your body isn't solid matter. It's made of energy. Your body seems and feels solid, but it isn't.
If you were to peer at your cells through an electron microscope, you would see a combination of waves and particles.
And these waves and particles in your cells understand sound. Yes, that's right, they understand the language of sound just as you understand these words.
Your cells absorb, translate, and use the sounds in the way they need to.
The magical thing about sound is that you don't have to know how it works. It just does.
With sound medicine you can treat your body and mind on their most fundamental level — as energy.
Sound medicine uses healing sounds to resonate, realign, harmonize, activate, and balance you on every level.
Some healing sounds are sounds of nature, your voice, crystal singing bowls, tuning forks, instruments, bells, gongs, and drums.
If you haven't tried a sound healing, be prepared for a magical experience!


This is a ladies mini dress, it has a wrap effect front with a deep v neckline and a low v back. The top is lurex which contrasts with the plain black skirt. Perfect for formal occasions. It is available in 4 different sizes and 1 colour to give you a variety to select from and find a perfect fit.


Hulu and Annapurna Pictures today announced a huge output licensing agreement that will grant Hulu the pay-one window streaming rights to films released by the film producer and distributor. This is Hulu's largest output deal for film to date as well as the first-of-its-kind agreement for Annapurna Pictures.
Under the new agreement, all of Annapurna's future films will be streamed exclusively on Hulu after their theatrical release. First up to the plate, coming to the platform on August 4, 2017, is the highly anticipated "Untitled Detroit Project," directed by Kathryn Bigelow.
Annapurna Pictures is the production company behind well known films such as "Zero Dark Thirty," "American Hustle," "Her," and "Sausage Party." To date, the company's films have amassed thirty-two Academy Award nominations.
"Annapurna Pictures has developed a well-known reputation of delivering standout, award winning films year after year. These are exactly the types of titles we look for to expand our film offering, and we are confident that our viewers will love watching their future slate of releases on Hulu," said Craig Erwich, SVP and Head of Content at Hulu.
The new deal follows a string of multi-year, pay one window output agreements with independent distributors including IFC Films for documentaries and Magnolia Pictures. In addition, Hulu has recently set deals with EPIX and The Walt Disney Studios.


text:
Even Rolling Stone is getting in on the Dropkick Murphys fever.
Dropkick Murphys Mend Sox
Boston punkers remake "Tessie" to end hometown baseball team's drought
No Boston baseball team has won the World Series since 1918, when Babe Ruth helped the Red Sox capture the title. But local punk rock heroes Dropkick Murphys may have found a way to end the curse with a song. The band has remade the old Broadway waltz "Tesse" for an upcoming EP, hoping the track's legacy will spur on the Sox to their first championship win in over eighty-five years.
Can a song really help? Turns out, "Tessie" is a real baseball legend. A rabid group of Irish-American baseball fans from South Boston known as the Royal Rooters started singing the old Broadway hit back in 1903 to rile opposing teams. It worked. During the inaugural World Series that year, the Red Sox (then known as the Pilgrims) were down four games to one in a best-of-nine series with Pittsburgh. The team had hired a band to inspire the players, but had run out of money to pay them. Desperate for anything that would help the team, the Rooters began to sing an a capella version of the Broadway song "Tessie" in the stands. Other fans joined in, and a performance of the song became a regular addition to all of the remaining games -- which were all won by Boston. They won the Series, and, until the Rooters disbanded and stopped singing the song in 1918, the Sox and their cross-town counterparts the Boston Braves would capture the pennant five more times.
"The vice-president of the Red Sox, Charles Steinberg -- he's a real baseball historian -- was excited about the prospects of the song," says Dropkick Murphys guitarist-singer Ken Casey. "He was like 'Maybe that would be a good thing to try.' And some people pointed out that, with our history of remaking traditional Irish songs, we might be a good band to take a stab at it."
Instead of a straightforward remake, the band radically altered the lyrics to reflect the story of how "Tessie" inspired the Boston teams to victory. Several Red Sox players, including star centerfielder Johnny Damon, added backup vocals. "You know, the original was some old lady on a piano singing about her parrot," says Casey, laughing. "I'm actually not sure how that translates to baseball."
The band will perform the track, along with the National Anthem, during Saturday's game with the Yankees at Fenway. An EP of the song, featuring an alternate version of the track and a remake of an old Boston Bruins theme song from the Seventies, will be released on August 1st. The EP will also feature a video that the band recently shot at Fenway Park.
"I'm a big Boston sports fan, and there's no question that the Red Sox are the number one team in town," Casey says. "We're just suckers for heartache, I guess. We know when we win it's going to be the biggest party in the world."
After "Tessie"'s release, the band will play the tenth annual Warped Tour show in Boston on August 20th, and then tour Europe and Japan in the fall. According to Casey, the Murphys' next release will actually be two CDs, both tentatively scheduled to come out next March. One will be an acoustic album of old and new tracks, and the other will be a singles collection.
(Posted Jul 23, 2004)
href='http://www.rollingstone.com/news/story?id=6376814&pageid=rs.Home&pageregion=single1' target='_blank'>rollingstone.com
The Lawrence Arms 'Skeleton Coast' Out Now!
Fake Names' Self-Titled Debut Out Now
The Frights Announce 'Live At The Observatory,' Available April 12

redpajama_set_name: RedPajamaCommonCrawl


We provide a service that will keep you, the customer, at ease during and after treatments. If you have a problem please contact us so we can bring your pest problem our pest control prevention and eradication services within 24hrs.
Most of these make their homes within our houses and businesses, some don't actually cause the issue, more so their larvae.
These are the most common moths to be found causing issues.
Global can deal with any moth problems you may have.


text:
My location Unknown
Lets you see shops near you!
Filters Open now
Open today after
Saturday 22 Jan Sunday 23 Jan Monday 24 Jan Tuesday 25 Jan Wednesday 26 Jan Thursday 27 Jan Friday 28 Jan Saturday 29 Jan Sunday 30 Jan
Hobbs- SOUTH MOLTON STREET London
Closed Later today -
Hobbs- OXFORD STREET London
Hobbs- Kensington High Street London
Hobbs- ARIEL WAY London
Hobbs- 15 Hampstead High Street London
Hobbs- MONTFICHET ROAD London
Hobbs- Prince Charles Drive London
Hobbs- Lancaster Place London
Hobbs- St. George's Road London
Hobbs- NORTH END Croydon
Hobbs- HIGH STREET Bromley
Hobbs- WOOD STREET Kingston Upon Thames
Hobbs- CHURCH STREET Kingston Upon Thames
Hobbs- THE TOWN Enfield
Hobbs- 52 The Harlequin Watford
Hobbs- STATION ROAD Upminster
Hobbs- LAKESIDE SHOPPING CENTRE Grays
Hobbs- Thurrock Lakeside Shopping Centre Grays
Hobbs- LOWER GUILD HALL Greenhithe
Hobbs- Unit 13/14 Christopher Place St. Albans
Hobbs- Jubilee Arch Windsor
Hobbs- Bridge Road Welwyn Garden City
Hobbs- THE BROADWAY Amersham
Hobbs- HIGH STREET Guildford
Hobbs- COUNTY MALL Crawley
Hobbs- NEWLANDS MEADOW High Wycombe
Hobbs- HIGH STREET Chelmsford
Hobbs – Women's Fashion And Accessories
Hobbs is a retailing chain selling women's garments, accessories and footwear. Some of their products include knitwear, skirts, jeans, casual clothes and office attire. They also sell shoes and accessories such as jewellery, belts, scarves, hats and much more. They have more than 130 stores across the UK. They also operate in Germany and the United States. Their online store supplies women's fashion products to a much wider market of over 50 countries. They aim to operate as a one-stop-shop for fashion and accessories with customers being able to complete their entire outfit in one shop.
Hobbs Opening Times And Store Locations
The company runs a chain of stores exceeding 130 establishments. These 130-and-more stores can be found in major shopping districts and high streets in major towns and cities. The company has dispersed their branches to more than 70 locations. This means some residents will have access to a nearby store and other residents may have easy access to multiple stores. UK residents that live in London, Glasgow or Sheffield will be afforded the most Hobbs stores within their nearby vicinity. Recognising one of their outlets is straightforward due to the company's recognisable branding and logo. The logo simply depicts the company name in a stylish font on a white background. The name of the company has the word "London" beneath it.
Hobbs opening times may change between their different locations for a number of reasons. It is recommended to search for a specific Hobbs store opening times near you by using the effective locator tool on opening-times.co.uk. Nevertheless, most stores do operate from a similar schedule. From Monday to Friday, many of their establishments are open between 9.30am and 6pm. Hours are extended on Saturdays by another 30 minutes as they open at 9am instead of 9.30am. Sunday business hours are reduced as most stores will be open from 11am until 5pm on these days. During the festive period and on New Year's Day, Good Friday, Easter Monday, and bank holidays, Hobbs opening times may change significantly or stores may close. During these times it is again recommended to use the aforementioned opening-hour checking tool to find the opening times of a Hobbs branch near you.
Five Things You Didn't Know About Hobbs
Hobbs has become part of the furniture in popular shopping areas throughout the UK. Their customers may know a lot about their products but there are aspects of the business and their operations that they may not be aware of, including:
Hobbs has attracted royal patronage with the Duchess of Cambridge and her sister Pippa Middleton shopping there
The company is actually named after a horsebox (the original concept was to sell clothing with an equestrian feel)
Hobbs have prime locations in Bloomingdale's stores in the USA
Hobbs, unlike many other retailers who source products from outside the company, own an Italian shoe-making factory
The factory makes 700 pairs of shoes each day - it focuses on high-end footwear
The retailer's range of products can be categorised into women's clothing, shoes and accessories. Their clothing department is extensive and includes dresses, skirts, casual wear, wedding and formal attire, coats, knitwear, jumpsuits and more. Their shoe department also has a wide range of options from sandals to heels with boots, pumps and more squeezed in between. Shoes may be branded or they may come from their own Italian-based factory. Their accessory range includes jewellery, scarves, belts, purses, bags and more. All of their range has become known to cater for women in their 30s and above looking for fashion at the upper end of the range. Clothes can be purchased in-store or can be bought online. Their website also runs a blog aimed to discuss trends and inspire outfits.
Two women by the names of Marilyn and Yoram Anselm started the company in 1981 with the ambition to sell everyday clothes with an equestrian feel. They started just selling footwear but expanded to also sell clothes gradually. Marilyn designed her own clothes after attending an art and design school. They have expanded into more countries by selling online and have a physical presence in two other countries. They continue to provide fashionable clothes to UK-based women.
More Clothing in the UK
Hobbs closed? Then try one of the other Clothing nearby.
Blue Inc
Bon Marche
Hobbs Opening Times
The regular opening times of most Hobbs establishments are from Monday to Friday 10AM-5PM, on Saturday 10AM-5PM and on Sunday 11AM-5PM. Find the actual opening hours of Hobbs in our branch locator.
Hobbs has over 140 establishments in the UK, London is the city with the most establishments followed by Glasgow and York. In total you will find this Clothing in over 90 cities. Select one of the locations for information about opening times today. We show hours for Sundays and late night shopping, Address, phone number and website information can also be found.
Hobbs.co.uk
About Hobbs
Hobbs offers a unique range of clothes and footwear and it's a retail company with an international presence despite being based in the UK. It is a company that has merged luxury and affordability in the design of its products which it claims can stand the test of time, remaining fashionable till the unforeseeable future. Hobbs has an atelier in London as well as a shoe factory in Italy from where its employees toil with a passion to produce quality products for their eagerly awaiting clients. Perfection and precision remain quite crucial to this company, with an attention to detail for stunning clothes and well-fitting and durable footwear. Hobbs makes products that will be suitable for any event. You can access their services from their many branches or through their website which caters for people in up to 50 countries.


text:
package com.jgraph.example.panelexample;

import javax.swing.tree.DefaultMutableTreeNode;

import org.jgraph.graph.CellView;

/**
 * A very basic wrapper storing a reference to a custom user object with a
 * label.
 *
 * @author rvalyi
 */
public class BusinessObjectWrapper2 {
	private String label = "";

	private CellView[] portviews;

	/**
	 * The wrapper where you put your real buisness object.
	 * (An other solution is that you business object
	 * implements a toString method and you deal with it
	 * in the editor)
	 */
	private DefaultMutableTreeNode value;

	public String getLabel() {
		return label;
	}

	public void setLabel(String stringValue) {
		this.label = stringValue;
	}

	public DefaultMutableTreeNode getValue() {
		return value;
	}

	public void setValue(DefaultMutableTreeNode value) {
		this.value = value;
	}

	/**
	 * Used by JGraph to render the cell label
	 */
	public String toString() {
		return label;
	}

	public CellView[] getPortviews() {
		return portviews;
	}

	public void setPortviews(CellView[] portviews) {
		this.portviews = portviews;
	}
}

redpajama_set_name: RedPajamaGithub


Welcome to Baywatch On Time!
We are specialists in sales and service of quality watches. All of our products are 100% genuine and are sourced from New Zealand suppliers backed with full manufacturer's warranties. Our aim is to provide our customers with the highest level of customer service.


text:
Q: Null pointer excpetion with opencsv CsvToBean I am trying to convert all rows in a CSV file into a java bean using openCSV.Each row has 21 columns in my file separated with pipe symbol(|).But getting null pointer exception with this code.rows in csv file include empty cells also.I am not able to figure out where is the error.can any one help me out
package com.alu.mdf.testsuite.sure;
import java.io.FileReader;
import java.util.List;
import com.opencsv.CSVParser;
import com.opencsv.CSVReader;
import com.opencsv.bean.ColumnPositionMappingStrategy;
import com.opencsv.bean.CsvToBean;

//import com.alu.mdf.test.common.Person;

    public class CSVExplorer {

        @SuppressWarnings({"rawtypes", "unchecked"})
        public static void main(String[] args) throws Exception
        {
            CsvToBean csv = new CsvToBean();

            String csvFilename = "TestCaseConfigurationFiles/application.csv";
            //CSVReader csvReader = new CSVReader;
            CSVParser csvParser=new CSVParser('|');
            CSVReader reader = new CSVReader(new FileReader(csvFilename),1,csvParser);

            //Set column mapping strategy
            List list = csv.parse(setColumMapping(), reader);

            for (Object object : list) {
                SUREDataBean SUREDataBean = (SUREDataBean) object;
                System.out.println(SUREDataBean);
            }
        }

        @SuppressWarnings({"rawtypes", "unchecked"})
        private static ColumnPositionMappingStrategy setColumMapping() throws Exception
        {
            ColumnPositionMappingStrategy strategy = new ColumnPositionMappingStrategy();
            strategy.setType(SUREDataBean.class);
            //strategy.createBean();
            String[] columns = new String[] {"InputDataStartIdentifier","EntityType","Operation","IncludeId","IdValue","AssociatedResource","SearchQueryForGETRequest/ParametersForPUTRequest","PayloadLocation","TestCaseName","Description","userName","password","InputDataEndIdentifier","ValidationDataStart","ExpectedStatusCode","VerficationParameters","Method","class","Prerequisites","Group","ValidationDataEnd"};
            System.out.println(columns.length);
            strategy.setColumnMapping(columns);
            return strategy;
        }

    }

Here is error stack trace:

Exception in thread "main" java.lang.RuntimeException: Error parsing CSV! at com.opencsv.bean.CsvToBean.parse(CsvToBean.java:95) at com.opencsv.bean.CsvToBean.parse(CsvToBean.java:75) at com.alu.mdf.testsuite.sure.CSVExplorer.main(CSVExplorer.java:28) Caused by: java.lang.NullPointerException at com.opencsv.bean.CsvToBean.processLine(CsvToBean.java:123) at com.opencsv.bean.CsvToBean.processLine(CsvToBean.java:101) at com.opencsv.bean.CsvToBean.parse(CsvToBean.java:91) ...

A: I think you'll have less trouble with uniVocity-parsers. It is also way faster than OpenCSV. To use it, first annotate your bean:
class SUREDataBean {

    @NullString(nulls = { "?", "-" }) // if the value parsed in the quantity column is "?" or "-", it will be replaced by null.
    @Parsed(defaultNullRead = "0") // if a value resolves to null, it will be converted to the String "0".
    private Integer quantity; // The attribute name will be matched against the column header in the file automatically.

    @Trim
    @LowerCase
    @Parsed
    private String comments;
    ...

}

To parse:
BeanListProcessor<SUREDataBean> rowProcessor = new BeanListProcessor<SUREDataBean>(SUREDataBean.class);

CsvParserSettings parserSettings = new CsvParserSettings();
settings.getFormat().setDelimiter('|');
parserSettings.setRowProcessor(rowProcessor);
parserSettings.setHeaderExtractionEnabled(true);

CsvParser parser = new CsvParser(parserSettings);

//Parsing is started here.
//this submits all rows parsed from the input to the BeanListProcessor
parser.parse(new FileReader(new File("/examples/bean_test.csv")));

List<SUREDataBean> beans = rowProcessor.getBeans();

Disclosure: I am the author of this library. It's open-source and free (Apache V2.0 license).

redpajama_set_name: RedPajamaStackExchange


text:
(function(){
    var chipLinksTest = angular.module('ChipLinksClient', ['chip-links']);

    chipLinksTest.config(function($logProvider){
        $logProvider.debugEnabled(true);
    });

    chipLinksTest.controller('ChipLinksClientCtrl', function($scope, $log) {
        $scope.chipLinkSelectHandler = function(chipLinkId) {
            $log.info("Chip link " + chipLinkId + " has been selected!");
        };
    });
})();


• Adult patients with chronic immune thrombocytopenia (ITP) who have had an insufficient response to corticosteroids, immunoglobulins, or splenectomy.
• Pediatric patients 1 year of age and older with ITP for at least 6 months who have had an insufficient response to corticosteroids, immunoglobulins, or splenectomy.
• Nplate is not indicated for the treatment of thrombocytopenia due to myelodysplastic syndrome (MDS) or any cause of thrombocytopenia other than chronic ITP [see Warnings and Precautions (5.1)].
• Nplate should be used only in patients with ITP whose degree of thrombocytopenia and clinical condition increases the risk for bleeding [see Warnings and Precautions (5.2)].
• Nplate should not be used in an attempt to normalize platelet counts [see Warnings and Precautions (5.2)].
Use the lowest dose of Nplate to achieve and maintain a platelet count ≥ 50 × 109/L as necessary to reduce the risk for bleeding. Administer Nplate as a weekly subcutaneous injection with dose adjustments based upon the platelet count response.
The prescribed Nplate dose may consist of a very small volume (e.g., 0.15 mL). Administer Nplate only with a syringe that contains 0.01 mL graduations.
See Section 2.3 for monitoring recommendations during Nplate therapy.
Discontinue Nplate if the platelet count does not increase to a level sufficient to avoid clinically important bleeding after 4 weeks of Nplate therapy at the maximum weekly dose of 10 mcg/kg [see Warnings and Precautions (5.3)].
The initial dose of Nplate is 1 mcg/kg. Actual body weight at initiation of treatment should always be used when calculating the initial dose. In adults, future dose adjustments are based on changes in platelet counts only.
Adjust the weekly dose of Nplate by increments of 1 mcg/kg until the patient achieves a platelet count ≥ 50 × 109/L as necessary to reduce the risk for bleeding; do not exceed a maximum weekly dose of 10 mcg/kg. In clinical studies, most adult patients who responded to Nplate achieved and maintained platelet counts ≥ 50 × 109/L with a median dose of 2 mcg/kg.
• If the platelet count is < 50 × 109/L, increase the dose by 1 mcg/kg.
• If platelet count is > 200 × 109/L and ≤ 400 × 109/L for 2 consecutive weeks, reduce the dose by 1 mcg/kg.
• If platelet count is > 400 × 109/L, do not dose. Continue to assess the platelet count weekly. After the platelet count has fallen to < 200 × 109/L, resume Nplate at a dose reduced by 1 mcg/kg.
The initial dose of Nplate is 1 mcg/kg. Actual body weight at initiation of treatment should always be used when calculating initial dose. In pediatric patients, future dose adjustments are based on changes in platelet counts and changes in body weight. Reassessment of body weight is recommended every 12 weeks.
Adjust the weekly dose of Nplate by increments of 1 mcg/kg until the patient achieves a platelet count ≥ 50 × 109/L as necessary to reduce the risk for bleeding; do not exceed a maximum weekly dose of 10 mcg/kg. In a pediatric placebo-controlled clinical study, the median dose was 5.5 mcg/kg.
To mitigate against medication errors (both overdose and underdose), ensure that these preparation and administration instructions are followed. Use aseptic technique. Only administer subcutaneously [see Overdosage (10)].
Nplate is supplied in single-dose vials as a sterile, preservative-free, white lyophilized powder that must be reconstituted as outlined in Table 1 and administered using a syringe with 0.01 mL graduations.
Multiply the patient's weight (kg) by the prescribed dose to obtain the Calculated Patient Dose.
Reconstitute Nplate with Sterile Water for Injection, USP. If the Calculated Patient Dose is less than 23 mcg, dilution with 0.9% Sodium Chloride Injection, USP is required. Follow instructions in Table 1.
* Actual vial content includes overfill to ensure delivery of calculated dose.
** Add Sterile Water for Injection, USP directly to the vial.
*** Add 0.9% Sodium Chloride Injection, USP directly to the vial.
Gently swirl and invert the vial to reconstitute. Avoid excess or vigorous agitation: DO NOT SHAKE. Generally, dissolution of Nplate takes less than 2 minutes. The reconstituted Nplate solution should be clear and colorless. Visually inspect the reconstituted solution for particulate matter and/or discoloration. Do not administer Nplate if particulate matter and/or discoloration is observed.
Initial reconstitution of Nplate with designated volumes of Sterile Water for Injection, USP results in a concentration of 500 mcg/mL in all vial sizes. Do not reconstitute or dilute with Bacteriostatic Water for Injection, USP or dilute with Bacteriostatic Sodium Chloride Injection, USP.
If a patient's dose is less than 23 mcg, then additional dilution with 0.9% Sodium Chloride Injection, USP is required. Dilution per reconstitution instructions results in reducing the concentration of Nplate from 500 mcg/mL to 125 mcg/mL in all vial sizes (see Table 1). This reduced concentration allows for low-doses to be accurately calculated, and consistently measured with a 0.01 mL graduated syringe.
Calculate Volume to Administer by dividing the Calculated Patient Dose (mcg) by the final concentration. See Table 2 for final concentrations.
Administer Nplate only using a syringe with 0.01 mL graduations for accurate dosage. Round volume to the nearest hundredth mL. Verify that the syringe contains the correct dosage.
Discard any unused portion. Do not pool unused portions from the vials. Do not administer more than one dose from a vial.
Reconstituted product with Sterile Water for Injection, USP that has not been further diluted can remain in the original vial at room temperature 25°C (77°F) or be refrigerated at 2°C to 8°C (36°F to 46°F) for up to 24 hours following reconstitution. Reconstituted product with Sterile Water for Injection, USP may be held in a syringe at room temperature 25°C (77°F) for a maximum of 4 hours following reconstitution. Protect product from light. Do not shake.
Reconstituted and further diluted product with 0.9% Sodium Chloride Injection, USP can be held in a syringe at room temperature 25°C (77°F) or in the original vial refrigerated at 2°C to 8°C (36°F to 46°F) for no longer than 4 hours prior to administration. Protect product from light. Do not shake.
Obtain CBCs, including platelet counts, weekly during the dose adjustment phase of Nplate therapy and then monthly following establishment of a stable Nplate dose. Obtain CBCs, including platelet counts, weekly for at least 2 weeks following discontinuation of Nplate [see Dosage and Administration (2.1)].
For injection: 250 mcg or 500 mcg of deliverable Nplate as a sterile, lyophilized, solid white powder in single-dose vials.
Progression from myelodysplastic syndromes (MDS) to acute myelogenous leukemia (AML) has been observed in adult clinical trials with Nplate.
A randomized, double-blind, placebo-controlled trial enrolling adult patients with severe thrombocytopenia and International Prognostic Scoring System (IPSS) low or intermediate-1 risk MDS was terminated due to more cases of AML observed in the Nplate arm. This trial consisted of a 58-week study period with a 5-year long-term follow-up phase. The subjects were randomized 2:1 to treatment with Nplate or placebo (167 Nplate, 83 placebo). During the 58-week study period, progression to AML occurred in 10 (6.0%) subjects in the Nplate arm and 4 (4.8%) subjects in the placebo arm (hazard ratio [95%CI] = 1.20 [0.38, 3.84]). Of the 250 subjects, 210 (84.0%) entered the long-term follow-up phase of this study. With 5-years of follow-up, 29 (11.6%) subjects showed progression to AML, including 20/168 (11.9%) subjects in the Nplate arm versus 9/82 (11.0%) subjects in the placebo arm (HR [95% CI] = 1.06 [0.48, 2.33]). The incidence of death (overall survival) was 55.7% (93/167) in the Nplate arm versus 54.2% (45/83) in the placebo arm (HR [95% CI] = 1.03 [0.72, 1.47]). In the baseline low IPSS group, there was a higher incidence of death in the Nplate arm [41.3% (19/46)] compared to the placebo arm [30.4% (7/23)] [HR (95% CI) = 1.59 (0.67, 3.80)].
In a single-arm trial of Nplate given to 72 subjects with thrombocytopenia-related MDS, 8 (11.1%) subjects were reported as having possible disease progression, of which 3 (4.2%) had confirmation of AML during follow-up. In addition, in 3 (4.2%) subjects, increased peripheral blood blast cell counts decreased to baseline after discontinuation of Nplate.
Thrombotic/thromboembolic complications may result from increases in platelet counts with Nplate use. Portal vein thrombosis has been reported in patients with chronic liver disease receiving Nplate.
To minimize the risk for thrombotic/thromboembolic complications, do not use Nplate in an attempt to normalize platelet counts. Follow the dose adjustment guidelines [see Dosage and Administration (2.1)].
Hyporesponsiveness or failure to maintain a platelet response with Nplate should prompt a search for causative factors, including neutralizing antibodies to Nplate [see Adverse Reactions (6.3)]. To detect antibody formation, submit blood samples to Amgen (1-800-772-6436). Amgen will assay these samples for antibodies to Nplate and thrombopoietin (TPO). Discontinue Nplate if the platelet count does not increase to a level sufficient to avoid clinically important bleeding after 4 weeks at the highest weekly dose of 10 mcg/kg.
The data described below reflect Nplate exposure to 271 adult patients with chronic ITP, aged 18 to 88, of whom 62% were female. Nplate was studied in two randomized, placebo-controlled, double-blind studies that were identical in design, with the exception that Study 1 evaluated nonsplenectomized patients with ITP and Study 2 evaluated splenectomized patients with ITP. Data are also reported from an open-label, single-arm study in which patients received Nplate over an extended period of time. Overall, Nplate was administered to 114 patients for at least 52 weeks and 53 patients for at least 96 weeks.
In the placebo-controlled studies, headache was the most commonly reported adverse drug reaction, occurring in 35% of patients receiving Nplate and 32% of patients receiving placebo. Headaches were usually of mild or moderate severity. Table 3 presents adverse drug reactions from Studies 1 and 2 with a ≥ 5% higher patient incidence in Nplate versus placebo. The majority of these adverse drug reactions were mild to moderate in severity.
Among 291 adult patients with chronic ITP who received Nplate in the single-arm extension study, the incidence rates of the adverse reactions occurred in a pattern similar to those reported in the placebo-controlled clinical studies.
An open-label clinical trial prospectively evaluated changes in bone marrow reticulin formation and collagen fibrosis in adult patients with ITP treated with Nplate or a non-US approved romiplostim product. Patients were administered romiplostim by SC injection once weekly for up to 3 years. Based on cohort assignment at time of study enrolment, patients were evaluated for bone marrow reticulin and collagen at year 1 (cohort 1), year 2 (cohort 2), or year 3 (cohort 3) in comparison to the baseline bone marrow at start of the trial. Patients were evaluated for bone marrow reticulin formation and collagen fibrosis using the modified Bauermeister grading scale. From the total of 169 patients enrolled in the 3 cohorts, 132 (78%) patients were evaluable for bone marrow collagen fibrosis and 131 (78%) patients were evaluable for bone marrow reticulin formation. Two percent (2/132) of patients (both from cohort 3) developed Grade 4 findings (presence of collagen). There was no detectable bone marrow collagen in one patient on repeat testing 12 weeks after discontinuation of romiplostim. Progression of bone marrow reticulin formation (increase greater than or equal to 2 grades or more) or an increase to Grade 4 (presence of collagen) was reported in 7% (9/131) of patients.
The data described below reflect median exposure to Nplate of 168 days for 59 pediatric patients (aged 1 to 17 years) with ITP for at least 6 months, of whom 47.5% were female, across the randomized phase of two placebo-controlled trials. Table 4 presents the most common adverse reactions experienced by at least 5% of the pediatric patients (1 year and older) receiving Nplate across the two placebo-controlled trials with at least a 5% higher incidence in patients who received Nplate compared to those who received placebo.
aMedDRA version 20.1 is used.
In pediatric patients of age ≥ 1 year receiving Nplate for ITP, adverse reactions with an incidence of ≥ 25% in the two randomized trials were: contusion (41%), upper respiratory tract infection (31%), and oropharyngeal pain (25%).
As with all therapeutic proteins, there is a potential for immunogenicity. The detection of antibody formation is highly dependent on the sensitivity and specificity of the assay. Additionally, the observed incidence of antibody (including neutralizing antibody) positivity in an assay may be influenced by several factors including assay methodology, sample handling, timing of sample collection, concomitant medications, and underlying disease. For these reasons, comparison of the incidence of antibodies to Nplate in the studies described below with the incidence of antibodies in other studies or to other products may be misleading. Patients were screened for immunogenicity to romiplostim using a BIAcore-based biosensor immunoassay. This assay is capable of detecting both high- and low-affinity binding antibodies that bind to romiplostim and cross-react with TPO. The samples from patients that tested positive for binding antibodies were further evaluated for neutralizing capacity using a cell-based bioassay.
In clinical studies in adult patients with ITP, the incidence of pre-existing antibodies to romiplostim was 5% (53/1112) and the incidence of binding antibody development during treatment with Nplate or a non-US approved romiplostim product was 4% (50/1112). The incidence of pre-existing antibodies to endogenous TPO was 4% (40/1112) and the incidence of binding antibody development to endogenous TPO during treatment was 3% (38/1112). Of the patients with positive binding antibodies that developed to romiplostim or to TPO, five patients had neutralizing activity to romiplostim and none had neutralizing activity to TPO. No apparent correlation was observed between antibody activity and clinical effectiveness or safety.
In pediatric studies, the incidence of binding antibodies to Nplate at any time was 7.8% (22/282). Of the 22 patients, 2 patients had pre-existing binding non-neutralizing Nplate antibodies at baseline. Additionally, 2.5% (7/282) developed neutralizing antibodies to Nplate. A total of 3.2% (9/282) patients had binding antibodies to TPO at any time during Nplate treatment. Of these 9 patients, 2 patients had pre-existing binding non-neutralizing antibodies to TPO. All patients were negative for neutralizing activity to TPO.
A post marketing registry study involving patients with thrombocytopenia on Nplate or a non-US approved romiplostim product was conducted to assess the long-term consequences of the anti-romiplostim antibodies. Patients who lacked response or lost response to Nplate or a non-US approved romiplostim product were enrolled. The incidence of new binding antibody development was 3% (5/186) to romiplostim and 1% (2/186) to TPO. One patient was positive for binding antibodies to both romiplostim and TPO. Of the five patients with positive binding antibodies to romiplostim, two (1%) were positive for neutralizing antibodies to romiplostim only.
Nineteen confirmed pediatric patients were included in the post marketing registry study. The incidence of binding antibody post treatment was 16% (3/19) to romiplostim, of which 5.3% (1/19) were positive for neutralizing antibodies to romiplostim. There were no antibodies detected to TPO.
Nplate may be used with other medical ITP therapies, such as corticosteroids, danazol, azathioprine, intravenous immunoglobulin (IVIG), and anti-D immunoglobulin [see Clinical Studies (14.1)].
Based on findings from animal reproduction studies, Nplate may cause fetal harm when administered to a pregnant woman (see Data). Limited available data with Nplate use in pregnant women are insufficient to inform a drug-associated risk of adverse developmental outcomes. In animal reproduction and developmental toxicity studies, romiplostim crossed the placenta, and adverse fetal effects included thrombocytosis, postimplantation loss, and an increase in pup mortality (see Data).
In rat and rabbit embryo-fetal development toxicity studies, no evidence of fetal harm was observed at romiplostim doses up to 11 times (rats) and 82 times (rabbits) the maximum human dose (MHD) based on systemic exposure (AUC). In mice at doses 5 times the MHD, reductions in maternal body weight and increased postimplantation loss occurred.
In a prenatal and postnatal development study in rats, at doses 11 times the MHD, there was an increase in perinatal pup mortality. Romiplostim crossed the placental barrier in rats and increased fetal platelet counts at clinically equivalent and higher doses.
Women who become pregnant during Nplate treatment are encouraged to enroll in Amgen's Pregnancy Surveillance Program. Patients or their physicians should call 1-800-77-AMGEN (1-800-772-6436) to enroll.
There is no information regarding the presence of romiplostim in human milk, the effects on the breastfed child, or the effects on milk production. Human IgG is present in human milk, but published data suggest that breast milk antibodies do not enter the neonatal and infant circulation in substantial amounts. Due to the potential for serious adverse reactions in a breastfed child from Nplate, advise women not to breastfeed during treatment with Nplate.
Safety and effectiveness have been established in pediatric patients age 1 year and older with ITP for at least 6 months evaluated in two randomized, placebo-controlled studies [see Adverse Reactions (6.1), Clinical Studies (14.2)]. The pharmacokinetics of romiplostim have been evaluated in pediatric patients 1 year and older with ITP [see Clinical Pharmacology (12.3)]. See Dosage and Administration (2.1) for dosing recommendations for pediatric patients 1 year and older. The safety and efficacy of Nplate in pediatric patients younger than 1 year with ITP have not been established. Serum concentrations of romiplostim in pediatric patients with ITP were within the range observed in adult patients with ITP receiving the same dose range of romiplostim.
Of the 271 patients who received Nplate in ITP clinical studies, 55 (20%) were age 65 and over, and 27 (10%) were 75 and over. No overall differences in safety or efficacy have been observed between older and younger patients in the placebo-controlled studies, but greater sensitivity of some older individuals cannot be ruled out. In general, dose adjustment for an elderly patient should be cautious, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.
Overdoses due to medication errors have been reported in patients receiving Nplate. In the event of overdose, platelet counts may increase excessively and result in thrombotic/thromboembolic complications. In this case, discontinue Nplate and monitor platelet counts. Reinitiate treatment with Nplate in accordance with dosing and administration recommendations [see Dosage and Administration (2.1, 2.2)].
Romiplostim, a member of the TPO mimetic class, is an Fc-peptide fusion protein (peptibody) that activates intracellular transcriptional pathways leading to increased platelet production via the TPO receptor (also known as cMpl). The peptibody molecule contains two identical single-chain subunits, each consisting of human immunoglobulin IgG1 Fc domain, covalently linked at the C-terminus to a peptide containing two thrombopoietin receptor-binding domains. Romiplostim has no amino acid sequence homology to endogenous TPO. Romiplostim is produced by recombinant DNA technology in Escherichia coli (E coli).
Nplate (romiplostim) for injection is supplied as a sterile, preservative-free, lyophilized, solid white powder for subcutaneous injection. Two vial presentations are available, which contain a sufficient amount of active ingredient to provide either 250 mcg or 500 mcg of deliverable romiplostim. Each single-dose 250 mcg vial of Nplate contains the following: 375 mcg romiplostim, 1.2 mg L-histidine, 30 mg mannitol, 0.03 mg polysorbate 20, 15 mg sucrose, and sufficient HCl to adjust the pH to a target of 5.0. Each single-dose 500 mcg vial of Nplate contains the following: 625 mcg romiplostim, 1.9 mg L-histidine, 50 mg mannitol, 0.05 mg polysorbate 20, 25 mg sucrose, and sufficient HCl to adjust the pH to a target of 5.0 [see Dosage and Administration (2.2)].
Nplate increases platelet production through binding and activation of the TPO receptor, a mechanism analogous to endogenous TPO.
In clinical studies, treatment with Nplate resulted in dose-dependent increases in platelet counts. After a single subcutaneous dose of 1 to 10 mcg/kg Nplate in patients with chronic ITP, the peak platelet count was 1.3 to 14.9 times greater than the baseline platelet count over a 2- to 3-week period. The platelet counts were above 50 × 109/L for seven out of eight patients with chronic ITP who received six weekly doses of Nplate at 1 mcg/kg.
In the long-term extension study in adult patients with ITP receiving weekly treatment of Nplate subcutaneously, the pharmacokinetics of romiplostim over the dose range of 3 to 15 mcg/kg indicated that peak serum concentrations of romiplostim were observed about 7 to 50 hours post dose (median: 14 hours) with half-life values ranging from 1 to 34 days (median: 3.5 days). The serum concentrations varied among patients and did not correlate with the dose administered. The elimination of serum romiplostim is in part dependent on the TPO receptor on platelets. As a result, for a given dose, patients with high platelet counts are associated with low serum concentrations and vice versa. In another ITP clinical study, no accumulation in serum concentrations was observed (n = 4) after six weekly doses of Nplate (3 mcg/kg). The accumulation at higher doses of romiplostim is unknown.
Serum concentrations of romiplostim in pediatrics with ITP were within the range observed in adult ITP patients receiving the same dose range of romiplostim. Similar to adults with ITP, romiplostim pharmacokinetics are highly variable in pediatric patients with ITP.
The carcinogenic potential of romiplostim has not been evaluated. The mutagenic potential of romiplostim has not been evaluated. Romiplostim had no effect on the fertility of rats at doses up to 37 times the MHD based on systemic exposure.
In a 4-week repeat-dose toxicity study in which rats were dosed subcutaneously three times per week, romiplostim caused extramedullary hematopoiesis, bone hyperostosis, and marrow fibrosis at clinically equivalent and higher doses. In this study, these findings were not observed in animals after a 4-week post treatment recovery period. Studies of long-term treatment with romiplostim in rats have not been conducted; therefore, it is not known if the fibrosis of the bone marrow is reversible in rats after long-term treatment.
The safety and efficacy of Nplate in adults with chronic ITP were assessed in two double-blind, placebo-controlled clinical studies and in an open-label extension study.
In Studies 1 and 2, patients with chronic ITP who had completed at least one prior treatment and had a platelet count of ≤ 30 × 109/L prior to study entry were randomized (2:1) to 24 weeks of Nplate (1 mcg/kg subcutaneous [SC]) or placebo. Prior ITP treatments in both study groups included corticosteroids, immunoglobulins, rituximab, cytotoxic therapies, danazol, and azathioprine. Patients already receiving ITP medical therapies at a constant dosing schedule were allowed to continue receiving these medical treatments throughout the studies. Rescue therapies (i.e., corticosteroids, IVIG, platelet transfusions, and anti-D immunoglobulin) were permitted for bleeding, wet purpura, or if the patient was at immediate risk for hemorrhage. Patients received single weekly SC injections of Nplate, with individual dose adjustments to maintain platelet counts (50 × 109/L to 200 × 109/L).
Study 1 evaluated patients who had not undergone a splenectomy. The patients had been diagnosed with ITP for approximately 2 years and had received a median of three prior ITP treatments. Overall, the median platelet count was 19 × 109/L at study entry. During the study, the median weekly Nplate dose was 2 mcg/kg (25th–75th percentile: 1–3 mcg/kg).
Study 2 evaluated patients who had undergone a splenectomy. The patients had been diagnosed with ITP for approximately 8 years and had received a median of six prior ITP treatments. Overall, the median platelet count was 14 × 109/L at study entry. During the study, the median weekly Nplate dose was 3 mcg/kg (25th–75th percentile: 2–7 mcg/kg).
Study 1 and 2 outcomes are shown in Table 5. A durable platelet response was the achievement of a weekly platelet count ≥ 50 × 109/L for any 6 of the last 8 weeks of the 24-week treatment period in the absence of rescue medication at any time. A transient platelet response was the achievement of any weekly platelet counts ≥ 50 × 109/L for any 4 weeks during the treatment period without a durable platelet response. An overall platelet response was the achievement of either a durable or a transient platelet response. Platelet responses were excluded for 8 weeks after receiving rescue medications.
a All p values < 0.05 for platelet response and rescue therapy comparisons between Nplate and placebo.
b For multiple concomitant baseline therapies, all therapies were discontinued.
In Studies 1 and 2, nine patients reported a serious bleeding event [five (6%) Nplate, four (10%) placebo]. Bleeding events that were Grade 2 severity or higher occurred in 15% of patients treated with Nplate and 34% of patients treated with placebo.
Patients who had participated in either Study 1 or Study 2 were withdrawn from study medications. If platelet counts subsequently decreased to ≤ 50 × 109/L, the patients were allowed to receive Nplate in an open-label extension study with weekly dosing based on platelet counts. Following Nplate discontinuation in Studies 1 and 2, seven patients maintained platelet counts of ≥ 50 × 109/L. Among 100 patients who subsequently entered the extension study, platelet counts were increased and sustained regardless of whether they had received Nplate or placebo in the prior placebo-controlled studies. The majority of patients reached a median platelet count of 50 × 109/L after receiving one to three doses of Nplate, and these platelet counts were maintained throughout the remainder of the study with a median duration of Nplate treatment of 60 weeks and a maximum duration of 96 weeks.
The safety and efficacy of Nplate in pediatric patients 1 year and older with ITP for at least 6 months were assessed in two double-blind, placebo-controlled clinical trials.
In Study 4, patients refractory or relapsed after at least one prior ITP therapy with a platelet count ≤ 30 X 109/L were stratified by age and randomized (2:1) to receive Nplate (n=42) or placebo (n=20). The starting dose for all ages was 1 ug/kg weekly. Over a 24-week treatment period, dose was titrated up to a maximum of 10 µg/kg weekly of either Nplate or placebo in an effort to maintain a target platelet count of ≥ 50 × 109/L to 200 × 109/L.
The median age of the patients was 9.5 years (range 3 to 17) and 57% were female. Approximately 58% of patients had a baseline count ≤ 20 x 109/L, which was similar between treatment arms. The percentage of patients with at least 2 prior ITP therapies (predominantly immunoglobulins and corticosteroids) was 81% in the group treated with Nplate and 70% in the group treated with placebo. One patient in each group had undergone splenectomy.
Study 4 results are shown in Table 6. The efficacy of Nplate in this trial was measured by the proportion of patients receiving Nplate achieving a durable platelet response and the proportion of patient achieving an overall platelet response. A durable platelet response was defined as achieving at least 6 weekly platelet counts ≥ 50 × 109/L during weeks 18 through 25 of treatment. A transient platelet response was defined as a weekly platelet count ≥ 50 × 109/L for 4 or more times during weeks 2 through 25, but without durable platelet response. An overall platelet response was defined as a durable or a transient platelet response. Platelet responses were excluded for 4 weeks after receiving rescue medications.
a All p values < 0.05 for platelet response between Nplate and placebo.
In study 5, patients diagnosed with ITP at least 6 months prior to enrollment with a platelet count ≤ 30 x 109/L were stratified by age and randomized (3:1) to receive Nplate (n=17) or placebo (n=5). The starting dose for all ages was 1 ug/kg weekly. Over a 12-week treatment period dose was titrated up to a maximum of 10 µg/kg weekly of either Nplate or placebo in an effort to maintain a target platelet count of ≥ 50 × 109/L to 250 × 109/L.
The median age of the patients was 10 years (range 1 to 17 years) and 27.3% of patients were female. Approximately 82% of patients had a baseline count ≤ 20 x 109/L, which was similar between treatment arms.
The percentage of patients with at least 2 prior ITP therapies (predominantly IVIG and corticosteroids) was 88% in the group treated with Nplate and 100% in the group treated with placebo. Six patients in the Nplate group and 2 patients in the placebo group had undergone splenectomy.
The efficacy of Nplate in this trial was measured by the proportion of patients who achieved a platelet count of ≥ 50 × 109/L for 2 consecutive weeks and by the proportion of patients who achieved an increase in platelet count of ≥ 20 × 109/L above baseline for 2 consecutive weeks. Platelet responses within 4 weeks following rescue medications use were excluded. Of the 17 patients who received romiplostim, 15 achieved a platelet count of ≥ 50 × 109/L for 2 consecutive weeks (88.2%, 95% CI: 63.6%, 98.5%).
The same 15 patients also achieved an increase in platelet count of ≥ 20 × 109/L above baseline for 2 consecutive weeks during the treatment period (88.2%, 95% CI: 63.6%, 98.5%). None of the patients treated with placebo achieved either endpoint.
Nplate (romiplostim) for injection is supplied as a sterile, preservative-free, solid white lyophilized powder in single-dose vials that deliver 250 mcg (NDC 55513-221-01) and 500 mcg (NDC 55513-222-01) of romiplostim.
Store Nplate vials in the refrigerator at 2° C to 8°C (36° F to 46°F) in the original carton to protect from light. Do not freeze.
If needed, unopened Nplate vials may be stored in the original carton at room temperature up to a maximum of 25°C (77°F) for a single period of up to 30 days. The new expiration date must be written in the space provided on the carton. Once stored at room temperature, do not place back in the refrigerator. If not used within the 30 days, discard Nplate.
Nplate therapy is administered to achieve and maintain a platelet count ≥ 50 × 109/L as necessary to reduce the risk for bleeding; Nplate is not used to normalize platelet counts.
Following discontinuation of Nplate, thrombocytopenia and risk of bleeding may develop that is worse than that experienced prior to the Nplate therapy.
Nplate therapy may increase the risk of reticulin fiber formation within the bone marrow. This formation may improve upon discontinuation. Detection of peripheral blood cell abnormalities may necessitate a bone marrow examination.
Too much Nplate may result in excessive platelet counts and a risk for thrombotic/thromboembolic complications.
Nplate stimulates certain bone marrow cells to make platelets and increases the risk of progression to acute myelogenous leukemia in patients with myelodysplastic syndromes.
Platelet counts and CBCs must be performed weekly until a stable Nplate dose has been achieved; thereafter, platelet counts and CBCs must be performed monthly while taking Nplate.
Patients must be closely monitored with weekly platelet counts and CBCs for at least 2 weeks following Nplate discontinuation.
Even with Nplate therapy, patients should continue to avoid situations or medications that may increase the risk for bleeding.
Advise women not to breastfeed during treatment with Nplate [see Use in Specific Populations (8.2)].
© 2008-2018 Amgen Inc. All rights reserved.
What is the most important information I should know about Nplate?
Worsening of a precancerous blood condition to a blood cancer (leukemia). Nplate is not for use in people with a precancerous condition called myelodysplastic syndromes (MDS), or for any condition other than chronic (lasting a long time) immune thrombocytopenia (ITP). If you have MDS and receive Nplate, your MDS condition may worsen and become an acute leukemia. If MDS worsens to become acute leukemia you may die sooner from the acute leukemia.
Higher risk for blood clots.
○ You may have a higher risk of getting a blood clot if your platelet count becomes high during treatment with Nplate. You may have severe complications or die from some forms of blood clots, such as clots that spread to the lungs or that cause heart attacks or strokes.
○ If you have a chronic liver disease, you may get blood clots in the veins of your liver. This may affect your liver function.
Your healthcare provider will closely monitor your Nplate dose and blood tests, including platelet counts during treatment.
Injection of too much Nplate may cause a dangerous increase in your blood platelet count and serious side effects.
Your healthcare provider may change your dose or stop Nplate, depending upon the change in your blood platelet count. You must have blood platelet counts done before you start, during, and after Nplate therapy is stopped.
See "What are the possible side effects of Nplate?" for other side effects of Nplate.
children 1 year of age and older with ITP for at least 6 months when certain medicines or surgery to remove your spleen, have not worked well enough.
Nplate is not for use in people with a precancerous condition called myelodysplastic syndrome (MDS), or low platelet count caused by any condition other than chronic (lasting a long time) immune thrombocytopenia (ITP).
Nplate is only used if your low platelet count and medical condition increase your risk of bleeding.
Nplate is used to try to keep your platelet count about 50,000 per microliter in order to lower the risk for bleeding. Nplate is not used to make your platelet count normal.
It is not known if Nplate is safe and effective in children under the age of 1.
are pregnant or plan to become pregnant. Nplate may harm your unborn baby. Tell your healthcare provider if you become pregnant or think you may be pregnant during treatment with Nplate.
Pregnancy Surveillance Program: Women who become pregnant during Nplate treatment are encouraged to enroll in Amgen's Pregnancy Surveillance Program. The purpose of this program is to collect safety information about the health of you and your baby. Contact the program as soon as you become aware of the pregnancy, or ask your healthcare provider to contact the program for you. You or your healthcare provider can get information and enroll in the program by calling 1-800-77-AMGEN (1-800-772-6436).
are breastfeeding or plan to breastfeed. Nplate may pass into your breast milk and harm your baby. Do not breastfeed during treatment with Nplate and for 2 weeks after the last dose.
Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal products. Know the medicines you take. Keep a list of them and show it to your healthcare provider or pharmacist when you get a new medicine.
How will I receive Nplate?
Before you receive Nplate you should first talk with your healthcare provider and understand the benefits and risks of Nplate.
Nplate is given under the skin (subcutaneous injection) one time each week by your healthcare provider.
Your healthcare provider will check your platelet count every week and change your dose of Nplate as needed. This will continue until your healthcare provider decides that your dose of Nplate can stay the same. After that, you will need to get blood tests every month. When you stop receiving Nplate, you will need blood tests for at least 2 weeks to check if your platelet count drops too low.
Tell your healthcare provider about any bruising or bleeding that occurs during treatment with Nplate.
If you miss a scheduled dose of Nplate, call your healthcare provider to schedule your next dose as soon as possible.
What should I avoid while receiving Nplate?
Avoid situations that may increase your risk of bleeding, such as missing a scheduled dose of Nplate. You should schedule your next dose as soon as possible and call your healthcare provider.
What are the possible side effects of Nplate?
People who take Nplate may have an increased risk of developing new or worsening changes in the bone marrow called "increased reticulin." These changes may improve if you stop taking Nplate. Your healthcare provider may need to check your bone marrow for this problem during treatment with Nplate.
You may also report side effects to Amgen at 1-800-77-AMGEN (1-800-772-6436).
General information about the safe and effective use of Nplate.
Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. You can ask your pharmacist or healthcare provider for information about Nplate that is written for health professionals.
What are the ingredients in Nplate?
© 2008-2018 Amgen Inc. All rights reserved. For more information go to www.Nplate.com.
*Reconstitute with 0.72 mL Sterile Water for Injection, USP.
Store at 2º to 8ºC (36º to 46ºF).
*Reconstitute with 1.2 mL Sterile Water for Injection, USP.


I love this illustrative book on movie hero Clint Eastwood. I've known Mr. Eastwood's work since Rawhide (I watched him in the '60s) and have enjoyed his work ever since. This book covers his breakthrough from Westerns (wasn't he just gorgeous?) to Dirty Harry, and then runs with his string of hit movies he either starred in or directed. Not just a pretty face, Mr. Eastwood is an Oscar-winning director who is known for his ability to bring films in quickly and for being cost-effective. I remember being petrified while watching his debut-as-a-director movie, Play Misty for Me, and have never forgotten the impact it made on me - forever in my mind, when I think of the Monterey/Carmel area, I see the rocks and trees outside the house. Not only is this man a man of film and direction, he's also a musician and has composed for movies as well. Some of my favorite (and meaningful) photos in this book inlude page 25 (Rowdy Yates), page 169 (Mystic River), and page 70 (Dirty Harry). There are many pictures from his movies, too: Paint Your Wagon, Two Mules for Sister Sara; Firefox; Pale Rider; Bridges of Madison County; Million Dollar Baby, and a million others. But, why no picture from Kelly's Heroes?
Conclusion - Definitely a necessary addition to any serious Clint Eastwood fan's memorabilia.


Landscape photographer Matt Pinner, of Dorset, has turned his lens on neighbouring Hampshire to produce this series of photographs for his book Hampshire in Photographs, details at the end of the slideshow.
Matt shot this photograph of Longstock, near Winchester in Hampshire in January 2018. He says his hands were frozen because it was -5C !


text:
Q: Normalizing a histogram in matlab I have a histogram
hist(A, 801)

that currently resembles a normal curve but with max value at y = 1500, and mean at x = 0.5. I want to normalize it, so I tried
h = hist(A, 801)
h = h ./ sum(h)
bar(h)

now I get a normal curve with max at y = .03, but a mean at x = 450.
how do I decrease the frequency so the sum is 1, while retaining the same x range?
A is derived from
A = walk(50000, 800, .05, 2, .25, 0)

where
function [X_new] = walk(N_sim, N, mu, T, sigma, X_init)

delt = T/N;
up = sigma*sqrt(delt);
down = -sigma*sqrt(delt);

p = 1./2.*(1.+mu/sigma*sqrt(delt));

X_new = zeros(N_sim,1);
X_new(1:N_sim,1) = X_init;

ptest = zeros(N_sim,1);

for i = 1:N

    ptest(:,1) = rand(N_sim,1);
    ptest(:,1) = (ptest(:,1) <= p);

    X_new(:,1) = X_new(:,1) + ptest(:,1)*up + (1.-ptest(:,1))*down;

end

A: The sum is 1 with your code as it stands.
You may want integral equal to 1 (so that you can compare with the theoretical pdf). In that case:
[h, c] = hist(A, 801); %// c contains bin centers. They are equally spaced
h = h / sum(h) / (c(2)-c(1)); %// normalize to area 1
trapz(c,h) %// compute integral. Should be approximately 1


Search California Jobs If you are searching for jobs in Riverside click here and search the jobs posted.
Find out how Tigerjobs.com can help you fill your jobs. Click here for information about our products and services.
If you need help finding candidates to fill your advertising, marketing and sales positions, Tigerjobs.com can work for you.
Séan McAlary, Broker - Homes & Loans - One Call Does it All ... Buy Borrow or Sell, Flag Pin Realty, Real Estate Center for homes and loans in Corona, Riverside and Orange, California.


Throughout my life I have found great pleasure in making connections. Whether it is pairing the right bottle of wine with a special meal, bringing a piece of theater to life by directing, or finding the perfect wedding dress for a bride-to-be (yes, I once worked with couture wedding dress designer, Matthew Christopher), I love finding those connections that together create more than the sum of their parts. This is what I bring to my career in Real Estate. Whether it is finding a new house or a business space, these places are more than just spaces, they are home to your future dreams.
Born and raised in Port Townsend, a Port Townsend High School graduate, and a one time Rhododendron Queen, I have never NOT known Port Townsend. With my intimate knowledge of this town, this county, this community, you can trust my ability to help you discern what will be right for you as a seller or as a buyer.
At the age of 18 I moved to NYC to pursue a degree in theatre at New York University. Post graduation, I began a career in the restaurant industry working for food industry giants such as Mario Batali, Joe Bastianach, and Wolfgang Puck. For 17 years, I worked as a Maître d', sommelier, and manager in award winning restaurants in NYC, Maui, and the Berkshires. I even worked here in PT at the Silverwater Café for a number of years! However it was not until the birth of my daughter, Isabel in the late spring of 2015 while living on the East Coast, that I knew it was time to come back home and put down roots once again in this Victorian Seaport and Arts Community here on the Salish Sea.
In Real Estate I am a matchmaker, helping you to sell or discover your next house, land or commercial space. Customer service is what my life has been based on, I want you to feel heard, understood and cared for. I believe that we can accomplish this, together.
Contact me and let us do this.


text:
How we manage your money
Every year, hundreds of individuals, schools, clubs and businesses generously donate money to help Addenbrooke's and the Rosie remain at the forefront of patient care. It is our job to make sure that money is spent carefully, and for the purposes for which it is given.
How we spent
your money in 2017/18
Charitable expenditure policy
Total income £8.7m
Total expenditure increased by 4%
Fundraising expenditure £1.4m
Charitable activities £8.6m
Charitable Spend: £8.6m
Of every pound that we spent in the year:
82p was spent on charitable purposes
16p on fundraising and the running of the charity and
2p on investment management.
Sir Jules Thorn Charitable Trust gave ACT £159,000 towards an MRi incubator
Patients using a renal ward at Addenbrooke's are to benefit from a more colourful and relaxed approach to hospital life thanks to a legacy from a Cambridge woman.
All I want for Christmas is… Whether you have an innovative idea, thoughts around service improvement, grand designs to improve your ward or clinic environment or are seeking investment for a research project, Addenbrooke's Charitable Trust (ACT) could help!
Celebrity Hunted fugitive hides out at Addenbrooke's
Celebrity chef, Jean-Christophe Novelli, who is currently appearing as a fugitive on the run on Channel 4's Celebrity Hunted for Stand Up To Cancer, stopped off at Addenbrooke's during one of the episodes, shining a light on the hospital where his son was treated for neuroblastoma two years ago.
First of two new emergency children's ambulance services for the East of England funded thanks to donations
Chariots of Fire race achieves children's ambulance halfway funding mark
Addenbrooke's Charitable Trust are over halfway to raising enough to fund an Emergency Children's Ambulance thanks to the recent Chariots of Fire event.
Addenbrooke's liver transplant appeal success gives precious hope to many
Addenbrooke's Charitable Trust (ACT) has reached its £250,000 liver transplant appeal target thanks to the generous support of incredible donors.


GE Automation Services employs over 300 associates in sixteen facilities throughout the U.S. offering expertise in such areas as batch and continuous processes, packaging and material handling, motion control systems, electrical systems, installation, and maintenance/repair. "After reviewing numerous options, we felt that the financial track record, strong management team, and compatible service offering, all pointed to MAVERICK Technologies as the best fit for this acquisition," stated Ricardo Artigas, President of Energy Services for GE Energy.
With this transaction, MAVERICK will also be acquiring the controlling interest of C.F. Picou Associates, Inc., a leading global provider of advanced process control design and implementation services based in Baton Rouge, LA. "MAVERICK's specific experience in control systems and their overall automation marketplace involvement are a perfect fit for our APC offerings," stated Dr. Jim Ford, President of C.F. Picou Associates. "We are very excited about joining the MAVERICK team," continued Ford.
This latest strategic move follows MAVERICK's recent announcement of the company's formation of and participation in the Global Systems Integrator Alliance (GSIA), a worldwide alliance of leading business consulting and integration firms. Both the Automation Services acquisition and the GSIA formation confirm MAVERICK's position as the largest independent provider of integrated automation, business, reliability, and service solutions for the manufacturing and distribution industries.
St. Louis-based MAVERICK Technologies is a next-generation operational consulting and systems integration firm, dedicated to raising business value through the innovative application of manufacturing automation, information technologies, asset reliability, and service solutions. MAVERICK's key strength is the ability to combine manufacturing domain expertise along with the design, integration, installation, and service of workable systems that rapidly drive business value from the plant floor to the annual report. MAVERICK's Business Value3 ™ approach combines discipline, talent, and passion to help customers worldwide realize swift, measurable results. MAVERICK's core operation includes 500 engineers and IT professionals in 25 locations across the U.S. in Albuquerque, NM; Atlanta, GA; Baton Rouge, LA; Birmingham, AL; Boston, MA; Charleston, SC; Charlotte, NC; Chicago, IL; Columbia, IL; Dallas, TX; Fairfield, CA; Houston, TX; King of Prussia, PA; Los Angeles, CA; Memphis, TN; Mobile, AL; Newark, NJ; O'Fallon, IL; Pensacola, FL; Phoenix, AZ; Pleasant Prairie, WI; Portland, OR; Seattle, WA; St. Louis, MO; and, Winston Salem, NC. For additional information, visit the MAVERICK Web site at www.mavtechglobal.com.


Good news to all Mitsubishi Starion owners. We sell heavy duty and top of the range Mitsubishi Starion HID Kit. The HID Kit is exclusively designed to solve all your light problems especially when driving during dark nights or the low visibility period. You have a reason to smile during the fall when the air is humid and sometimes making it difficult to see the road. Assuredly there is no reason to knock objects or to loose direction and plunge into a ditch if you could get these HID headlights and HID Conversion Kit to give you the brightest lights ever. The HID Kit has a proven ISO-9001 mark of quality making it the only HID Kit in the market with an international ovation. The E-Mark will make you see even clearer how it is unique. You don't need to be worried, our prices are after market and whenever you buy the HID Kit or part of the Kit, you will certainly get a 1 year warranty. Installation is just simple and our installation manual will even make it easier.


text:
LS VISION - Top & Professional Solar Powered Camera System Manufacturer Since 2010.
ABOUT LSVISION
Solar Cameras
Low Power Wifi Solar Cameras
Low Power 4G Solar Cameras
CCTV DC12V 4G Solar Cameras
Smart Home WIFI Cameras
WIFI Battery Powered Cameras
WIFI Doorbell Cameras
WIFI Pan Tilt Cameras
2MP IP Camera
4K IP Camera
PTZ IP Camera
4 Channel NVR
16 Channel NVR
128 Channel NVR
Wireless PTZ
20X Hight Speed PTZ
Smart Security System
Face Recognition Kits
Face Capture Cameras
Face Recognition Cameras
Face Recognition NVRs
People Counting cameras
POE Security Camera Systems
4K POE NVR Kits
Wireless WiFi NVR Kit
Access Control Attendance System
Access Control Attendance Cameras
Access Control Temperature Detection Terminal
Thermal Imager for Measuring Human Body Temperature
Industrial Thermal Imaging Cameras
4G Body Camera
Ordinary Body Camera
Love Foundation
Solar Camera Wifi: The Ideal CCTV Camera for You
Solar security cameras, unlike conventional wired CCTV cameras, do not need running cables to connect to power sources
Subscribe to be hear about our latest arrivals!
Technological growth is never constant and it is always a distinguished experience to use the newest technology. And such is the solar camera wifi. These camera devices are well-equipped to address many of the issues of protecting a vast area in a distant location.
Solar-powered security cameras are self-contained units that do not require hard wiring to operate. They are powered by solar panels (included or available separately) and provide consumers with greater flexibility than wired security cameras.
These security systems are ideal for homes, offices, and distant, off-grid settings such as farms, cottages, and construction sites. Before you look for the finest solar-powered security camera for your building, you should understand how security camera's function, their distinct advantages, and the elements to consider while shopping for them.
What Is a Solar Camera Wifi?
Solar security cameras, unlike conventional wired CCTV cameras, do not need running cables to connect to power sources. They use Wi-Fi instead of data cords to communicate with home security systems. Wireless security cameras are simpler to set up and provide more positioning options. Therefore, in one word, a solar camera wifi is a normal solar camera that uses a wifi connection to run its processes.
How Do Wired and Wireless Cameras Differ?
When security cameras initially became available, they required a connected electricity supply to function. Some multi-camera systems still function in this manner. These connected cameras, transfer video signals to a viewing device, such as a computer monitor or television, through video cables.
The video signal, and in some cases the audio signal, from a wireless security camera, is transmitted over the internet or another wireless network to a receiver that links to your viewing and recording device. Many individuals store video recordings on PCs or cloud storage accounts for later viewing.
How Does a Solar Camera Wifi Work?
During the day, the solar panel transforms incident solar energy into electricity. The electricity will be kept in the battery system to produce light at night and power the camera throughout the day.
The HD camera's functionality is to capture films and photos. The data will be sent over the internet connection. You may monitor your surroundings from wherever you are using a live feed on your mobile phone or laptop. Additionally, the data may be saved on an SD card or the cloud.
The battery technology of a solar camera wifi determines how long the camera can operate when there is no sunshine. The finest solar-powered security cameras feature batteries that can run for at least 12 hours even when the sun isn't shining. Some variants can run for up to three days on battery power.
Some Common Features
The characteristics of solar power CCTV differ according to the source. Some may provide capabilities such as automated number plate recognition (ANPR), while others may not. On the other hand, solar power CCTV often has the following features:
● 24/7/365 solar-powered 360-degree detection area
● Audio capabilities in both directions
● 4G antenna with high gain
● Strong steel frame and anti-vandal casing
● Audio communication in both directions
● If an intrusion happens, warning lights will illuminate.
● Remote access service
● 24/7 storage recording
● System for detecting tampering
Benefits of A Solar Camera Wifi
A solar camera wifi has many benefits, such as:
● A PV system outdoor camera can operate endlessly by capturing the sun's energy using solar panels and is not powered by electricity cables. Furthermore, many current solar-powered security camera systems include a battery backup that allows them to operate at night.
● It's worth noting that the solar camera setup is quite inexpensive. The cost of solar CCTV cameras has dropped dramatically in recent years, mostly because of the increased availability of the materials required to manufacture solar panels. Furthermore, tax breaks are increasing the appeal of solar CCTV cameras. Governments, throughout the world, grant tax breaks to households and businesses that use renewable energy.
● Solar-powered CCTV surveillance systems have become extremely scalable as a result of technological breakthroughs such as 4G cellular connectivity. Thanks to 4G technology, modern solar camera wifi can instantly save what they capture in the Cloud. This tool allows users to monitor their properties from anywhere in the world.
● Another significant advantage is that solar-powered CCTV cameras do not require manual charging of their batteries. A sturdy battery will be able to save enough energy to provide high resolution video surveillance for your space. Also, these gadgets have no wires, so they are easy to move and install. They are very portable and can even be easily carried to remote areas.
A Couple of Drawbacks
Though these are known mostly for their varying advantages, a few cons also exist.
● If the camera's battery runs out entirely and the solar panel does not get enough light to create electricity, the camera's operation will be disrupted. This will affect the operation's stability.
● As solar-powered security cameras employ Wi-Fi or 4G LTE technology, it is not surprising that they may experience a poor wireless signal, an unreliable Wi-Fi connection, or even signal interference. Depending on your Wi-Fi environment or the location where the camera will be put, these issues can range from minor to moderate.
How To Choose the Right Solar Camera Wifi?
It is difficult to select solar camera wifi because they differ in many ways from their competitors in terms of quality. When purchasing a camera, we should seek higher resolution, a larger field of view, and the inclusion of capabilities that we will deem essential in 2022, such as two-way communication, night vision, and cloud storage possibilities.
We may also thoroughly test cameras to ensure that all functionalities function properly. Smart alerts are useless if they are 20 seconds late, and a siren is useless if it is barely heard. Some cameras frequently disconnect, and some apps are difficult to comprehend or manage. This is the point at which your decision becomes one of the wisest. If the test results are unsatisfactory, you may return.
Like All technological advancements, the CCTV system has also improved a lot over the decades. And ultimately researchers have put in such an intense effort that this technology is now within everyone's reach. Undoubtedly this technology will develop more in the future as well. But if this is not the ideal time to think of having a security system of your own, none is. And in these technological advancements, LS VISON can be your best association.
LS VISION Team
PREV What is the Best Solar Camera System At LS VISION
Why Solar Panel Security Cameras Are Smart Choice | LS VISION NEXT
Go fast
Copyright © 2021 Shenzhen LSVISION Technology Co., Ltd. All Rights Reserved.


Motorcycle Rearview Mirror Dual Camera Moto Dash Cam Video Camcorder 2.4 CODE: KCYU 04/13 PRICE:P2000 This motorcycle is an instrument that records videos and sounds while driving and provides crucial evidence of traffic accidents (a tip we DO NOT recommend changing video files, these actions may cause a corrupted evidence. you can also use it to record the process of conquering mountains or other obstacles. it is also capable of recording time, speed and location, just like a "black box" for motor vehicles.
1year used but my sister is out of country.


Rolling Meadows, Ill., November 3, 2014 — Cambium Networks™, a global leading provider of wireless broadband solutions, today unveiled its new community forum. With designated sections for asking and answering questions, reading about products, making suggestions and sharing stories. The forum is a hub for fixed wireless broadband practitioners and those interested in learning more about it.
"Over the past three years, Cambium Networks has continuously welcomed customer feedback and dialogue. We are pleased today to extend this engagement to a wider audience: Anyone can read what's happening on our forum and join in on the conversation. It is our hope that this global community will foster stronger ties among communities involved and interested in furthering the reach of fixed wireless broadband." said Atul Bhatnagar, president and CEO, Cambium Networks.


Ib Skills Science A Practical Guide Teachers Book is good choice for you that looking for nice reading experience. We hope you glad to visit our website. Please read our description and our privacy and policy page.
Finally I get this ebook, thanks for all these Ib Skills Science A Practical Guide Teachers Book can get now!


text:
© Pauline Opmeer/MUVA
Breaking barriers: work for women and work for men in Chamanculo, Mozambique
Author: Maria Ybarra Enguiz, Astrid Groenbaek
Published by: ALIGN
MUVA is a female economic empowerment programme funded by the UK's Department for International Development (DFID). The programme works in Mozambique's towns and cities, testing innovative ways to help young and disadvantaged women find decent employment opportunities. To change attitudes and social norms around women in the labour market, MUVA works with both young women and men.
This case study from Chamanculo in Maputo outlines the work of the MUVA Green project to rehabilitate green spaces to challenge gender norms in the civil construction sector.
"Tap, tap, tap…" this is the sound of pickaxes and spade at work. Local people pass this building site all the time, and it is a meeting point for the community and many other activities. Here there is a marketplace where you can eat badjia (bean dumplings fried in oil) or see grandpa playing his game of ntxuva (known as African chess) under the warm sun, while children play with skipping ropes.
It was this space that inspired the MUVA Green project in the Maputo neighbourhood of Chamanculo. Over four months in 2018, the project set out to rehabilitate green spaces – including this square where local people could come together.
Those watching our work had their doubts and asked themselves, "Will they really manage to re-construct our square?" What really intrigued them was to see a construction team that was 70% female. But the hard work and strength demonstrated by the women over the following days and weeks gradually earned them the respect and admiration of the community. The square took on a new life, but the impact went further, as the workers themselves began to broaden their horizons.
In the first cycle of this initiative, the MUVA Green project worked on the rehabilitation of three public spaces, with a team of 27 young people from the neighbourhood (70% women, 30% men and two people with disabilities). Of these 27 participants, only two men had any previous experience in civil construction. What's more, they had never worked with women before and, at first, didn't want the women to do "men's work."
We were aware that by allowing women to work on a construction site we would be challenging the social norms that say there is no space for women in construction. That is why technical training in gardening and paving was combined with an introductory workshop on gender and work, organised by Assoçiäcao Unidos Para Ajudar (UPA), a Mozambican association with extensive experience in training young people from disadvantaged communities in soft skills, attitudes and professional skills, to prepare them for the labour market. Participants were also offered collective mentoring sessions to build their self-esteem, courage and strength to meet challenges both on and off the job.
The work itself was managed by MUVA (which provided an engineer who supervised the construction site, as well as gender specialists who carried out the training) and LIVANINGO, a Mozambican organisation that led interactions between the participants and the wider community. This mentoring helped to create a cohesive group that supported each other so that no-one dropped out and the whole group stayed together right through to the end of the project.
In addition to the collective challenges of the building work itself, the team soon realised that gender relations and social norms were the principal challenges that women confronted in the civil construction sector.
Let's put ourselves in the shoes of a young woman from a neighbourhood like Chamanculo, who leaves the house each day wearing a helmet and boots to go and work in a male-dominated profession and, more than that, in a team generally composed mainly of men. Just by being herself, and through her example, she becomes an agent of change for her community.
As one young woman told us: "MUVA Green gave me a different vision, both in my own life and in the community; today people praise what I do, they recognise the strength and dedication I have."
But we also faced existing challenges in the wider system in which we all live and work. It was difficult, for example, to find construction equipment suitable for women. One specific example was that we could not find work boots anywhere in Maputo that had the steel toes you need for construction sites in sizes 36 or 37. This meant that at least half the women in the team did not have the right boots to ensure their safety on-site, and we had to improvise with a different type of tough boot found in the market until we could source the right sizes for the women. Even so, by the end of the project, these women could wield a shovel and pickaxe, lay bricks and paving stones and prepare concrete in the same way as their male colleagues.
Before the intervention, 50% of the young women in the group believed that men were better than women at doing this work. After the project 83% disagreed with this statement. The testimony of these women shows that they now see women and men as equals and have far greater belief in themselves:
"I can do it" said one. "What a man can do I can also do" said another.
The men in the group also changed their opinions:
"It is important to work with women and men," said one man "because I saw that both are intelligent and special, in different ways."
An experience that affected the team so clearly, also influenced the community in a very positive way. As one of the local residents explained "it was interesting and good to see the girls at work because it showed us they had capacity to work in construction."
Based on this experience, it is recommended that engineers and architects who want to create a more inclusive construction sector begin to look past quantities or construction plans. It is also vital to invest in the people who undertake the work and who construct the buildings brick by brick, with mentoring, support and training on self-esteem, groupwork, ethics and power relations. In this way we believe that we can both, build physical infrastructures, and begin to deconstruct harmful gender norms that restrict access of young women to decent work; transforming the way in which society views women in the economy.
For more information about this and other MUVA projects, visit muvamoz.co.mz, or follow MUVA on Facebook, Instagram or Twitter.
Maria Ybarra Enguiz
Maria is an architect and urban planner who worked with MUVA on the Green initiative. She is committed to inclusive urban design and the empowerment of young women in the areas of infrastructure and urban planning.
Astrid Groenbaek
Astrid was a MEL consultant at Oxford Policy Management at the time of the project and worked with the team to develop the MEL framework. She has a mixed methods background and for her the project was an exciting opportunity to employ a mix of methods to help the team understand the project's change path.